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ABSTRACT
Streptococcus pneumoniae is the leading bacterial cause of community-acquired respiratory tract
infections. Prior to the 1970s this pathogen was uniformly susceptible to penicillin and most other
antimicrobials. However, since the 1990s there has been a signiﬁcant increase in drug-resistant
Streptococcus pneumoniae (DRSP) due, in large part, to increased use of antimicrobials. The clinical
signiﬁcance of this resistance is not deﬁnitely established, but appears to be most relevant to speciﬁc
MICs for speciﬁc antimicrobials. Certain b-lactams (amoxicillin, cefotaxime, ceftriaxone), the respiratory
ﬂuoroquinolones, and telithromycin are among several agents that remain effective against DRSP.
Continued surveillance studies, appropriate antimicrobial usage campaigns, stratiﬁcation of patients
based on known risk factors for resistance, and vaccination programmes are needed to appropriately
manage DRSP and limit its spread.
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INTRODUCTION
Streptococcus pneumoniae is the most signiﬁcant
bacterial pathogen associated with community-
acquired respiratory tract infections (RTI). It is
particularly an important cause of community-
acquired pneumonia (CAP) for which it is the
most common cause of mortality. It is therefore,
essential that empirical therapy of CAP include
antimicrobial agents effective for this pathogen.
The decision concerning appropriate empirical
therapy has become more complicated because
of the emergence of strains resistant to penicillin
and other antimicrobials. However, the rele-
vance of drug-resistant S. pneumoniae (DRSP) in
relation to the clinical outcome of CAP is
controversial.
This article reviews the clinical signiﬁcance of
DRSP, with a focus on CAP, and its effect on the
approach to management.
S . PNEUMONIAE : MOST COMMON
CAUSE OF CAP
Despite the emergence of newly identiﬁed path-
ogens as a cause of CAP, S. pneumoniae remains
the most commonly identiﬁed cause. A meta-
analysis of 122 reports of CAP showed that
S. pneumoniae accounted for two-thirds of cases
in which etiological diagnosis was made, as well
as for two-thirds of the deaths [1].
The majority of studies that have evaluated the
aetiology of CAP have involved hospitalised
patients, where laboratory processes are more
likely to be available for diagnosis. However,
when patients were stratiﬁed by disease severity
[ambulatory, hospitalised (nonsevere) and inten-
sive care unit (ICU) (severe])], S pneumoniae was
the most common cause of CAP among patients
in all settings [2].
PNEUMOCOCCAL RESISTANCE
Historically, clinicians prescribed b-lactams or
other antimicrobials for empirical treatment of
community RTIs with little concern about the
susceptibility of the pneumococcus to the chosen
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antimicrobial. However, during the past decade
there has been an increase in antimicrobial resist-
ance of S. pneumoniae [3,4]. The ﬁrst reports of
clinical resistance of S. pneumoniae to penicillin
appeared in the 1960s, nearly 20 years after the
introduction of penicillin G [5]. In the 1970s,
pneumococcal resistance to penicillin and other
antimicrobials was documented in South Africa,
and in the 1980s, pneumococcal resistance was
reported in many European, African, and Asian
countries [5]. In the United States, few strains of
pencillin-resistant S. pneumoniae (PRSP) were
recovered in a surveillance programme conduct-
ed by the Centers for Disease Control and
Prevention (CDC) in the 1980s [6]. However, a
sharp increase in the prevalence of PRSP occurred
in the United States in the early 1990s. The results
of antimicrobial surveillance studies demonstrate
that the prevalence of penicillin-nonsusceptible
S. pneumoniae (PNSP) in the United States was
approximately 18% in 1990–91 and almost 35%
by 2002 [7]. Similar trends of increasing S. pneu-
moniae resistance to penicillin have been observed
worldwide (Table 1) [8]. High-level penicillin
resistance (i.e., penicillin MIC‡ 2.0 mg ⁄L) among
S. pneumoniae has increased to a greater degree
during the past 10 years than has intermediate
resistance (MIC between 0.12 and 1.0 mg ⁄L)
(Fig. 1) (Doern, personal communication, 2002).
Resistance of S. pneumoniae to the macrolides
has also increased over the past decade (Table 1).
In the United States, the prevalence of resistance
to newer macrolides (e.g., azithromycin, clarith-
romycin) among S. pneumoniae isolates is similar
to that of erythromycin (approximately 24%) [8].
The most common mechanisms of resistance
include erm-mediated methylation of the ribo-
somal target and efﬂux of the macrolides by a cell
membrane protein transporter, encoded by mef
S. pneumoniae strains which contain mef are
resistant at a lower level (most with MICs gener-
ally 1–32 mg ⁄L) than erm-encoded strains. The
‘mef-encoded’ strains are usually susceptible to
clindamycin. Most erm-encoded isolates have an
MIC > 64 mg ⁄L to erythromycin and are consid-
ered highly resistant to all macrolides and clin-
damycin. Currently mef-associated resistance
predominates in North America. Erm-associated
resistance predominates in Europe and is com-
mon in Japan [9].
Although the worldwide prevalence of pneu-
mococcal resistance to the newer ﬂuoroquinolo-
nes (levoﬂoxacin, gatiﬂoxacin, moxiﬂoxacin,
gemiﬂoxacin) remains low (less than 2%), in
some countries resistance has increased signiﬁ-
cantly [10–13] The prevalence of pneumococcal
isolates in Canada with reduced susceptibility to
ﬂuoroquinolones increased from 0% in 1993 to
1.7% in 1997–98 [12]. The overall prevalence
of ﬂuoroquinolone resistance (levoﬂoxacin >
4 mg ⁄L) in Hong Kong in 2000 had increased
to 13.3% due to the dissemination of a ﬂuoro-
quinolone-resistant clone [10]. Risk factors
for levoﬂoxacin resistance were identiﬁed as:
prior exposure to a ﬂuoroquinolone, nursing
home residence, nosocomial infection, and
COPD [13].
Telithromycin has been introduced into
numerous countries over the past few years.
To date, there is very little evidence of increas-
ing resistance [14–16]. In one recent surveillance
study of 31 000 isolates of S. pneumoniae collec-
ted from patients with community RTIs from
2000 to 2003, 99% were susceptible to telithro-
mycin [16].
Table 1. Comparative prevalences of penicillin and eryth-
romycin resistance in Streptococcus pneumoniae (MICs ‡ 2.0
and ‡ 0.5 mg ⁄L, respectively). Modiﬁed from Jacobs et al.,
2003 [8]
Location Penicillin resistance (%) Erythromcyin resistant (%)
Brazil 1.1 3.3
The Netherlands 1.1 3.8
Russia 1.2 6.2
Germany 1.9 6.9
Italy 4.3 35.2
UK 10.9 13.0
South Africa 17.9 19.8
Saudi Arabia 21.7 13.2
Mexico 22.2 25.0
Singapore 24.8 36.8
USA 25.0 28.8
Spain 26.4 27.5
Japan 28.5 71.0
France 40.5 53.2
Hong Kong 69.9 80.3
Fig. 1. Trends in penicillin resistance among Streptococcus
pneumoniae in the United States (Doern 2002, personal
communication). *Number of centres contributing isolates.
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Of particular concern when selecting an appro-
priate antimicrobial for empirical treatment of
CAP is the increasing prevalence of multidrug
resistance that has been documented with S. pneu-
moniae. Multidrug resistance and cross-resistance
to other antimicrobials are common with S. pneu-
moniae. Among S. pneumoniae respiratory isolates
evaluated in a recent worldwide surveillance
programme the prevalence of strains multidrug-
resistant to at least three among erythromycin,
doxycycline, choramphenicol, cotrimoxazole, or
oﬂoxacin was 17.5% overall, ranging from 0% in
centres in The Netherlands to 76% in Hong Kong
centres [8]. From this study, and of the strains from
theUS thatwere intermediately or fully resistant to
penicillin, 49.8% and 72.4%, respectively, also
were resistant to macrolides ⁄ azalides [8]. In the
recent study by Doern et al. 22.2% of isolates were
found to be multidrug resistant (deﬁned in this
study as nonsusceptible to penicillin plus nonsus-
ceptible to at lest two of the following four agents:
erythromycin, trimethoprim-sulfamethoxazole,
chloramphenicol, and tetracycline) [7].
DRIVERS OF RESISTANCE
Factors that may drive resistance include antimi-
crobial consumption, particularly antimicrobial
use in the past 3 months, inappropriate use of
antimicrobials (i.e., use when not indicated such
as for viral RTIs and suboptimal dosages), clonal
spread of multidrug-resistant strains, and pres-
ence of comorbidities. A study from Spain dem-
onstrated that an increase in the use of penicillin
was associated with an increase in penicillin-
nonsusceptible isolates [17]. Hyde and colleagues
(2001) demonstrated that the use of macrolides in
children was associated with an increase in
macrolide resistance [18]. Similarly, Chen and
colleagues (1999) showed that an increase in the
use of ciproﬂoxacin in Canada correlated with
emergence of ciproﬂoxacin resistance among
pneumococci.
Recent and inappropriate use of antimicrobials
is also independent to risk factors for develop-
ment of resistance [19,20]. In a study by Guillemot
and colleagues (1998), b-lactam use within the
past 30 days [odds ratio (OR), 3.0; conﬁdence
interval (CI), 1.1–8.3], doses lower than clinically
recommended (OR, 5.9; CI, 2.1–16.7), and treat-
ment for more than 5 days (OR, 3.5; CI, 1.3–9.8)
were identiﬁed as risk factors for penicillin-
resistant pneumococcal nasopharyngeal carriage
[19]. A recent study by Yu and colleagues (2003)
evaluated the clinical relevance of bacteraemic
pneumococcal pneumonia and the underlying
factors associated with the development of resist-
ance [21]. The two factors that were shown to be
independently associated with resistance on mul-
tivariate analysis were underlying disease (i.e.,
heart, liver, renal, or lung disease, or diabetes
mellitus) (OR, 2.1; p < 0.0001) and prior antimi-
crobial therapy (OR, 1.9; p < 0.0091).
Other risk factors for DRSP include alcoholism,
immunosuppressive illness or therapy, medical
comorbidities (i.e., congestive heart disease, dia-
betes, liver or kidney disease, chronic lung dis-
ease, cancer), and exposure to others at high risk
for carriage of DRSP (e.g., children who attend a
day care centre). The relative predictive value of
all these factors is unclear. Treatment with recent
antimicrobials is likely to be the most signiﬁcant
factor predictive of DRSP.
When strains of bacteria develop resistance, the
resistance can spread, especially in the presence
of extensive use of antimicrobials. Most of the
DRSP strains in the United States are of ﬁve
different serotypes, and the dominant factor of
emergence of PRSP in the United States has been
the result of human-to-human spread of a few
clonal groups [22].
ECONOMIC IMPACT OF CAP DUE TO
DRSP
Several studies have shown that resistant pneu-
mococcal infection in patients who require hospi-
talisation is associated with increased length of
stay [23,24], mortality [23,25], and cost of care
[23,26]. A case-control study in Iceland from 1988
to 1994 demonstrated increased costs from pneu-
monia caused by penicillin-resistant S. pneumoniae
(PRSP) based on prolonged hospitalisations and
use of expensive antimicrobial agents [23]. Results
from a more recent study from ten New York
hospitals conducted between 1998 and 2000 dem-
onstrated that PRSP is associated with a longer
stay (9.7 days vs. 7.9 days) and greater total direct
inpatient costs ($6262 vs. $4011) [26]. Although
the clinical relevance of DRSP is controversial,
there are economic consequences associated with
the management of patients who are infected with
strains of S. pneumoniae that are resistant to
commonly used antimicrobials.
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RELEVANCE OF DRSP TO CLINICAL
OUTCOME
B-lactams
The clinical relevance of DRSP in meningitis is
well understood. We know that adequate antimi-
crobial concentrations in the cerebrospinal ﬂuid
(CSF) must be attained to kill bacteria at that site,
and that high concentrations can overcome low
and intermediate levels of resistance. Penicillin
breakpoints have been deﬁned according to CSF
concentrations in which an MIC of 0.06 mg ⁄L or
less is considered susceptible, an MIC of 0.12–
1.0 mg ⁄L is intermediate, and an MIC of 2 mg ⁄L
or more is resistant (NCCLS, 2000). In CAP, the
clinical relevance of resistance has been less well
understood. Data on mortality rates from penicil-
lin-susceptible and b-lactam-resistant S. pneumo-
niae are conﬂicting. Several studies controlling for
potential confounding factors (i.e., age, underly-
ing disease, severity of illness) have not shown a
difference in mortality between patients with
penicillin-susceptible pneumococci and those
with PRSP [21]. However, many studies included
S. pneumoniae isolates with intermediate suscepti-
bility to penicillin, which may not be as clinically
relevant with regard to patient outcomes in CAP
as infection with highly resistant (MIC ‡ 4 mg ⁄L)
isolates [3].
In a prospective, 10-year study in Spain, mor-
tality was not correlated with resistance even
though resistance to penicillin, cephalosporins,
and erythromycin increased during the study per-
iod [27]. In contrast, several studies have shown a
signiﬁcant association between mortality and
high-level penicillin resistance (MIC ‡ 4 mg ⁄L)
in S. pneumoniae [25,28,29]. In a study from
the CDC, investigators found that after hospital
day 4, the risk of death was seven times
greater in patients infected with high-level PRSP
(MIC ‡ 4.0 mg ⁄L; 19 ⁄ 1151 patients) than in pa-
tients infected with intermediate isolates
(MIC ‡ 0.012–1.0 mg ⁄L; 81 ⁄ 1151) [25]. However,
treatment and severity of disease were not recor-
ded. In a trial of 192 patients, medical outcomes
(in-hospital mortality, medical complication rates,
and time to clinical stability) in patients with
bacteraemic pneumococcal pneumonia caused by
penicillin-susceptible strains of S. pneumoniaewere
compared with those in patients infected with
PNSP [28]. Compared with patients infected with
penicillin-susceptible strains, patients infected
with PNSP (MIC ‡ 0.12 lg ⁄L) had a greater risk
of in-hospital death due to pneumonia [relative
risk (RR), 2.1; 95% CI, 1–4.3]. In addition, the risk
of suppurative complications of infection was
increased in patients infected with PNSP (RR, 4.5;
95% CI, 1.0–19.3). However, after adjustment for
baseline differences in severity of illness, only the
risk of suppurative complications of infection
remained statistically signiﬁcant (adjusted RR,
4.8; 95% CI, 1.2–18.8). In an international, pros-
pective, observational study of 844 patients, an
association was identiﬁed among age, severity of
illness, and co morbidity, but not with whether
the isolates were PRSP [21]. Similar results were
found in the follow-up, case-control study of
patients with bacteraemic pneumococcal pneu-
monia, which addressed the limitations of the
trial by Feikin and colleagues and controlled for
risk factors, severity, and treatment [30]. The
ﬁndings from this multivariate analysis showed
no contribution of antimicrobial resistance to
mortality or requirement for ICU, but determined
that more important predictors of outcome inclu-
ded severity of illness and whether there was a
‘do not resuscitate’ order on the patient’s chart.
Thus, based on present data, it appears that
current levels of penicillin resistance do not
adversely affect outcomes for CAP in immuno-
competent patients as long as the MIC is <
4.0 mg ⁄L (the majority of nonsusceptible isolates)
[31–34]. In part, because of these data, the
National Committee for Clinical Laboratory
Standards (NCCLS; now renamed the Clinical
Laboratory Standards Institute, CLSI) recently
increased the MIC breakpoints for cefotaxime,
ceftriaxone and amoxicillin for nonmeningeal
infections, recognising that infections such as
pneumonia due to strains formerly considered
nonsusceptible can be treated successfully with
the usual doses of these b-lactam drugs.
Macrolides
Until recently reports of failure in cases of CAP
treated with macrolides has been rare, partic-
ularly for patients at low risk for drug-resistant
strains. However, since 2000, anecdotal reports
and a controlled study have documented failures
due to macrolide-resistance in patients treated
with an oral macrolide who have subsequently
required admission to the hospital with S. pneu-
moniae bacteraemia [35–38]. The clinical relevance
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of macrolide-resistant S. pneumoniae may be
dependent on the type of resistance expressed
by a particular strain. In-vitro resistance may not
result in treatment failures for levels of resistance
that can be exceeded by tissue levels of certain
macrolides [39]. Notably, of the two major mech-
anisms of macrolide resistance, the efﬂux pump
that confers the mef phenotype is associated with
levels of resistance that may be exceeded in vivo
(particularly if the MIC is < 8 and one of the
newer macrolides ⁄ azalides that achieve higher
levels in the tissue is used) while the ribosomal
target modiﬁcation that confers the MLSB pheno-
type is associated with levels of drug resistance
that almost certainly exceed the levels of drug
achievable in vivo (however, mef strains may also
exhibit high MICs which would affect the efﬁcacy
of the newer agents). Thus, the interpretation of
studies examining the impact of macrolide resist-
ance on bacteriological and clinical outcomes
must be conducted in light of the dominant
mechanisms of resistance (and their MICs) in-
volved in the study population.
Fluoroquinolones
Several cases of treatment failure due to ﬂuoro-
quinolone resistant pneumococcal infections in
adults with CAP have also been reported [40–42].
These reports include cases in which resistance
was present at the start of therapy or emerged
during therapy and both types of patients experi-
enced delayed clinical improvement. Fluoroqui-
nolone resistance has manifested clinically as
levoﬂoxacin treatment failure in patients with
levoﬂoxacin-resistant S. pneumoniae infection.
Many of the patients described in these recent
reports had been previously treated with ﬂuoro-
quinolones.
TREATMENT CONSIDERATIONS FOR
ANTIMICROBIAL-RESISTANT
PNEUMOCOCCAL CAP
Decisions concerning antimicrobial therapy are
guided by several considerations such as spec-
trum of activity, pharmacokinetics, efﬁcacy, safety
proﬁle, cost and concern for resistance. Despite
the controversies concerning the clinical relevance
of DRSP (at least for some antimicrobials), there is
enough concern on the part of most clinicians that
the decision for initial empirical management of
CAP has become more complicated. In this
context, the approach to appropriate therapy for
community RTIs entails several principles. These
include: appropriate use of antimicrobials, choice
of the most appropriate agent when antimicrobi-
als are indicated, and prevention of DRSP.
Appropriate use of antimicrobials
In the face of growing antibacterial resistance,
we must recognise that overuse of antimicrobi-
als is the prime driver of this resistance;
therefore, judicious antibiotic usage is para-
mount. Principles of optimised therapy should
be promoted and utilised by prescribing clini-
cians in order to achieve the best outcomes for
our patients and reduce the emergence of
antibiotic resistance. Many appropriate antibi-
otic-use initiatives have been published or
implemented over the past several years and
they appear to be having a positive effect in
reducing the overuse of antimicrobials for com-
munity RTIs as well as resulting in reduced
resistance [43–45]. Ball et al. have published a
list of principles for appropriate antimicrobial
prescribing which were developed by an inde-
pendent, multinational, interdisciplinary group
[43]. The goal of these principles is to maximise
beneﬁcial patient outcomes and counter bacter-
ial resistance.
The Group listed several core principles of
antibiotic therapy that should provide optimal
beneﬁt for patients as well as minimise resistance;
among these are:
1 Use antibacterial therapy only in those patients
with bacterial infection.
2 Utilise diagnostic and other measures to reduce
prescribing.
3 Therapy should maximally reduce or eradicate
the bacterial load.
4 Use antimicrobial agents with optimal phar-
macodynamics to achieve eradication.
5 Use locally relevant resistance data in the
decision process.
6 Understand that antimicrobial acquisition cost
may be insigniﬁcant compared with therapeutic
failure.
Optimal Drug Selection for DRSP
If antibiotic therapy is warranted, it is important
to select the right drug, dose and duration of
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therapy. Appropriate empirical therapy for infec-
tions for which S. pneumoniae is a consideration
requires awareness of local susceptibility pattern.
The in-vitro activity against S. pneumoniae of
several antimicrobials collected worldwide and
collected separately in the USA is presented in
Table 2. Those agents for which greater than 95%
of isolates are susceptible include: the respiratory
ﬂuoroquinolones, telithromycin, ceftotaxime, cef-
triaxone, amoxicillin (with or without clavula-
nate), linezolid, rifampin, and vancomycin. Since
community-acquired RTIs may also be caused by
pathogens other than S. pneumoniae (i.e., Haemo-
philus spp., atypical organisms), and since the
initial clinical manifestations of illness do not
reliably predict the aetiology, agents which are
also effective for these other possible pathogens
may be preferable for empirical therapy when risk
for DRSP is present. Single agents effective
against DRSP, Haemophilus spp., and the atypical
pathogens include: the respiratory ﬂuoroquinolo-
nes and telithromycin.
In addition to in-vitro activity, appropriate
antibiotic therapy should be guided by pharmac-
odynamics (PD). Integration of MIC values with
pharmacokinetic (PK) parameters provides
PK ⁄PD indices, which are valuable tools to
predict antibacterial effects and guide optimal
drug dosage [46]. Based on present PK ⁄PD
principles, high-dose amoxicillin (amoxicillin 1 g
three times a day or amoxicillin ⁄ clavulanate
2 g ⁄ 125 mg twice a day) should be effective
for > 95% of S. pneumoniae infections and is the
preferred oral b-lactam for community RTIs when
DRSP is a consideration [8]. Similarly, the third
generation cephalosporins, cefotaxime and ceftri-
axone, are active against the majority of DRSP and
can be used conﬁdently for infections of the
respiratory tract. On the contrary, the use of
cefuroxime, which has a lesser PK ⁄PD index than
cefotaxime or ceftriaxone, has been associated
with clinical failure in the context of DRSP [21]. Of
the respiratory ﬂuoroquinolones, based on
PK ⁄PD indices, gemiﬂoxacin and moxiﬂoxacin
are more potent than gatiﬂoxacin and levoﬂoxacin
against S. pneumoniae, although, the clinical rele-
vance of this is not deﬁnitively established [47].
Numerous clinical trials have documented the
efﬁcacy of the respiratory ﬂuoroquinolones,
telithromycin, and high dose amoxicillin in the
treatment of DRSP [47–49]. In a pooled analysis of
several prospective randomised trials using a
pharmacokinetically enhanced formulation of
amoxicillin ⁄ clavulanate (2000 ⁄ 125 every 12 h) in
RTIs, the success rate for infections due to PRSP
(penicillin MICs of 2–16 mg ⁄L) was 98.2% (55 ⁄ 56)
[48]. A recent pooled analysis by Low et al.
determined the activity of telithromycin by in-
vitro susceptibility testing of key respiratory tract
pathogens isolated from subjects with CAP,
AECB, and ABS who were enrolled in telithro-
mycin trials, in order to correlate this data with
the observed clinical outcomes [49]. In the pooled
bacteriologic modiﬁed intent-to-treat population,
telithromycin treatment for 5 or 7–10 days resul-
ted in an overall clinical cure rate of 88.1%
(1593 ⁄ 1808) and a rate of satisfactory bacteriolog-
ical outcome of 89.0% (1593 ⁄ 1789). In cases
involving infection with key respiratory patho-
gens, the following clinical cure and bacterial
eradication rates were achieved with telithromy-
cin: S. pneumoniae, 92.7% and 94.3%; H. inﬂuenzae,
87.0% and 85.6%; and M. catarrhalis, 89.7% and
89.7%, respectively.
Use of ﬂuoroquinolones for CAP
The development of the respiratory ﬂuoroquino-
lones has had a major impact on the management
Table 2. In-vitro susceptibility of Streptococcus pneumoniae
Antimicrobial
Study
Jacobs et al.a Doern et al.b
PK/PD3
(% Susceptible)
NCCLS
(% Resistant) % Resistant
Penicillin NA 18.2 18.5
Amoxicillin 95.1 2.1 5.3
Amoxicillin ⁄Clav 95.7 2.1 4.6
Amoxicillin ⁄Clav (2000 ⁄ 125) 97.9 NA NA
Cefuroxime 78.6 19.7 21.6
Ceftriaxoned 95.1 0.6 1.6
Erythromycin 75.3 24.6 28.6
Azithromycin 75.5 24.1 27.4
Clarithromycin 74.3 24.4 26.9
Clindamycin NA 13.9 9.3
Tetracycline NA NA 15.6
Doxycycline 71.3 NA NA
Chloramphenicol 88.1 11.9 4.7
Co-trimoxazole 63.3 24.8 25.4
Rifampin NA NA 0.2
Levoﬂoxacin 98.9 1.1 0.7
Gatiﬂoxacin 98.5 1.5 0.7
Moxiﬂoxacin 98.9 1.1 0.2
Gemiﬂoxacin 99.9 NA 0.2
Vancomycin NA NA 0
Linezolid NA NA 0
Qiunuprisitin-dalfopristin NA NA 0.025
aWorldwide surveillance (1998–2000), modiﬁed from Jacobs et al., 2003 [8]; bFrom 44
US Medical Centres (2002–03), modiﬁed from Doern et al., 2005 [7]; cBased on
pharmacokinetic ⁄pharmacodynamic breakpoints; dNon-meningeal breakpoints
(resistance ‡ 4 mg ⁄L).
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of CAP. Since the introduction of levoﬂoxacin in
1997, and the subsequent availability of gatiﬂoxa-
cin, moxiﬂoxacin, and gemiﬂoxacin, these agents
have been increasingly used in North America
and other parts of the world. At the same
time several compounds have been withdrawn
because of serious safety concerns.
These agents have made excellent choices for
treatment of CAP because of their intrinsic activ-
ity against the key pathogens-including DRSP
and the ‘atypical’ organisms, and they penetrate
well into pulmonary sites of infection. The emer-
gence of DRSP and increased awareness of the
‘atypical’ pathogens inﬂuenced the use of the
ﬂuoroquinolones. Additional advantages include
once daily dosing and high bioavailability. This
latter property has enhanced approaches to
treatment of CAP by: (1) providing potent oral
therapy for patients who otherwise may have
required hospitalisation; (2) allowing more rapid
IV-to-oral switch; and (3) allowing oral therapy
for selected patients who require hospitalisation.
In addition, several randomised clinical trials
have compared monotherapy using a respiratory
ﬂuoroquinolone with ‘standard’ therapy and
found an advantage in favour of the ﬂuoroqui-
nolone.
However, with the widespread use, and the
possible misuse, of these agents, there is concern
about the emergence of resistance including S.
pneumoniae, Enterobacteriaciae, and Pseudomonas
aeruginosa. Appropriate use of these agents is of
paramount concern. Stratiﬁcation of patient risk
factors for correct use and application of PK ⁄KD
parameters may lead to better clinical outcomes
and decrease the emergence of resistance.
Recommendations for treatment of DRSP
within guidelines
The selection of the right drug may be facilitated
by guidelines, which can be an effective tool to
promote appropriate antibiotic use as they dis-
courage the use of antibiotics to treat viral RTI
infections and can promote speciﬁc use of anti-
microbials according to patient risk factors for
DRSP [50]. As indicated earlier in this section
there are several available agents effective against
DRSP. The pertinent question becomes: do we
need to treat all patients empirically as if they
have DRSP? The answer must take into consid-
eration the relative rate of DRSP within a com-
munity and, to a lesser extent, the mechanism of
resistance (e.g., mef vs. erm for macrolide resist-
ance). In locations where the rate of DRSP is
relatively low it seems reasonable to reserve
agents such as the ﬂuoroquinolones and telithro-
mycin. An important principle in many of the
guidelines for community RTIs is to reserve the
ﬂuoroquinolones and telithromycin for patients
with mild infection who are more likely to be
infected with such strains in an attempt to avoid
over use of these agents.
The general North American approach is to
choose among macrolides, doxycycline, a respir-
atory ﬂuoroquinolone (e.g., gatiﬂoxacin, gemiﬂ-
oxacin, levoﬂoxacin, moxiﬂoxacin), or the
combination of a b-lactam plus macrolide as
treatment options for patients who are mildly ill
and can be treated as outpatients (Table 3) [51–
53]. More recently telithromycin has also been
included as an option since its introduction into
the market in 2004 [54]. The speciﬁc selection is
related to the relative likelihood of DRSP based on
the known risk factors as listed previously.
Usually, the North American guidelines recom-
mend a macrolide as ﬁrst-line treatment for
outpatients with no comorbidity or risk factors
for DRSP. The rationale is that the macrolides
provide effective therapy for the most common
bacterial pathogens, primarily S. pneumoniae
(which have been, up until the present, mostly
macrolide-responsive in North America) as well
as the ‘atypical’ organisms (especially M. pneu-
moniae and Chlamydophila pneumoniae which are
common in outpatients). The positioning of the
macrolides as prominent ﬁrst line agents in these
guidelines is partially based on the presumption
that resistance is less likely in patients who do not
have any of the know risk factors for DRSP. In
addition, the newer macrolides (azithromycin and
clarithromycin) may be effective against MRSP
strains in which lower-level resistance results
from increased drug efﬂux with MIC values often
< 8 mg ⁄L. However, because recent data indicate
that mef-mediated resistance is becoming associ-
ated with higher MICs (from a median of 4–
8 mg ⁄L), it is reasonable to consider alternative
therapy (i.e., respiratory ﬂuoroquinolone, or high
dose amoxicillin (‡ 3 g ⁄day for and adult) +
macrolide) if risk factors for DRSP are present.
Despite the reports of clinical failures in patients
with pneumococcal pneumonia treated with
macrolides as outpatients, the numbers are relat-
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ively small in light of the large number of patients
treated [50]. In addition, when such patients were
hospitalised and treated with a b-lactam and a
macrolide they generally survived. Most of these
patients had risk factors for which monotherapy
with a macrolide is not recommended in the
present guidelines. Thus, for patients without
signiﬁcant risks for DRSP or Gram-negative
bacilli, monotherapy with macrolide can at pre-
sent still be considered appropriate. The use of
ﬂuoroquinolones in ambulatory CAP without
comorbid conditions or recent antimicrobial use
in locations without a high percentage of high
level macrolide-resistant pnemococcus is discour-
aged for fear that widespread use may lead to the
development of ﬂuoroquinolone resistance
among the respiratory pathogens (as well as other
pathogens colonising the treated patients).
In contrast, the presence of risk factors for
DRSP (i.e., recent use of antibiotics, multiple
comorbities, etc.) increases the likelihood for
DRSP and enteric gram-negative bacteria. For
such outpatients, empirical therapeutic options in
the North American statements include: a respir-
atory ﬂuoroquinolone (gatiﬂoxacin, gemiﬂoxacin,
levoﬂoxacin, moxiﬂoxacin); a ketolide alone (i.e.,
telithromycin), if enteric Gram-negatives are not a
concern or combination therapy with a b-lactam
effective for S. pneumoniae plus a macrolide
(doxycycline as alternative) [53]. These regimens
can also be appropriate for patients without
comorbidities or recent antimicrobial use in loca-
tions where the prevalence of high-level macro-
lide-resistant S. pneumoniae is high (which
includes most countries outside of North Amer-
ica).
In comparison with the North American
approach, the primary agents recommended in
the recently published British Thoracic Society
guidelines for outpatients are b-lactams, basic-
ally penicillins, and not macrolides [55]. The
rationale is that these agents are effective
against S. pneumoniae, and when given in high
doses are even effective for most strains with
decreased sensitivity to penicillin. Since most of
the macrolide resistance in Europe is erm-medi-
ated high-level resistance, the macrolides are not
regarded as optimal ﬁrst-line empirical agents to
treat infections if they are considered likely to
be due to S. pneumoniae. In addition the British
statement places less signiﬁcance on the need to
treat the ‘atypical’ pathogens empirically in
ambulatory patients (mild disease). Rather, the
statement suggests that since M. pneumoniae
exhibits epidemic periodicity every 4–5 years
and largely affects younger persons, a policy for
initial empirical therapy that aims always to
cover this pathogen was unnecessary.
For patients requiring admission to a general
ward in the hospital, North American and Euro-
Table 3. Comparison of recommendations of recently published guidelines for empirical antimicrobial treatment of
community-acquired pneumonia in adults (from North America and United Kingdom)
Guideline Outpatienta General Warda ICU ⁄ Severea
North American Guidelines
(synthesis from Canadian,
2000; ATS, 2001, IDSA, 2003)
[50–52]
If no signiﬁcant risks for DRSPb:
Macrolidec or doxycycline
If risks for DRSPb:
Antipneumococcal ﬂuoroquinoloned
OR High-dose amoxicillin (3 g ⁄day)
or amoxicillin ⁄ clavulanate + macrolide
(if amoxicillin is used and there is
a concern for H. inﬂuenzae, use agent
active for b-lactamase producing strainsc)
OR Telithromycine
b-lactam (ceftriaxone, cefotaxime,
ampicillin ⁄ sulbactam) + macrolidec
(can use doxycycline if macrolide
not tolerated) OR
Antipneumococcal
ﬂuoroquinoloned alone
b-lactam (ceftriaxone, cefotaxime,
ampicillin ⁄ sulbactam) + macrolidec
or ﬂuoroquinoloned (if b-lactam
allergy, use ﬂuoroquinoloned +
clindamycin) Modifying factors
Structural lung disease: antipseudomonal
agent (piperacillin ⁄ tazobactam,
carbapenem, or cefepime) +
antipseudomonal ﬂuoroquinolone
(high dose ciproﬂoxacin or levoﬂoxacin)
British Thoracic Society
(2001) [53]
Amoxicillin 500–1000 mg, three times
a day (Alternative: erythromycin
or clarithromycin)
If admitted for nonclinical reasons or
previously untreated in the community:
amoxicillin (macrolide as alternative).
If admitted for pneumonia and oral
therapy appropriate: amoxicillin +
[erythromycin or clarithromycin];
(Alternative: antipneumococcal
ﬂuoroquinolone) If Parenteral appropriate:
[ampicillin or benzylpenicillin] +
[erythromycin or clarithromycin]
(Alternative: IV levoﬂoxacin)
(Deﬁned as severe) Co-amoxiclav or
2nd ⁄ 3rd gene ceph plus [IV
erythromycin or clarithromycin + ⁄ –
rifampin] (Fluoroquinolone with
enhanced pneumococcal activity +
benzylpenicillin as alternative)
aSite of care; ICU, intensive care unit; DRSP, drug resistant Streptococcus pneumoniae; bb-lactam therapy within the past 3 months, hospitalisation within the past month,
alcoholism, immune-suppressive illness (including therapy with corticosteroids), multiple medical comorbidities, exposure to a child in a day care centre; cIf COPD, use a
macrolide active against b-lactamase producing H. inﬂuenzae (i.e., azithromycin, clarithromycin); dGatiﬂoxacin, Levoﬂoxacin, Moxiﬂoxacin; eTelithromycin is not listed in the
published North American guidelines since it was not approved until after the most recently published statement, however, it is recommended as an option in a more recent
recommendation [53] and is included here for completeness.
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pean recommendations begin to converge. The
view here is that these patients require broader
coverage, and that recommended agents should
cover both S. pneumoniae (including consideration
for DRSP) and Legionella spp. (as well as
more unusual pathogens). In North America,
the ﬁrst-line recommendation for these patients
is a b-lactam–macrolide combination or one of the
new ﬂuoroquinolones. In Europe, a b-lactam (e.g.,
benzylpenicillin) –macrolide combination is the
widely recommended ﬁrst-line treatment for
patients requiring parenteral therapy. New ﬂuor-
oquinolones are beginning to be recommended
more frequently throughout Europe in the hospi-
tal setting.
Preventing DRSP through vaccination
The introduction of the conjugate pneumococcal
vaccine for children appears to be reducing the
amount of DRSP in those locations where it is
being utilised. The heptavalent vaccine includes
two serotypes that most commonly cause anti-
microbial-resistant disease in children. One study
has shown that 2 years after the use of the vaccine
in the US, the incidence of infection due to DRSP
diminished by 35% [56]. In addition, the use of
the conjugate vaccine may reduce antimicrobial
resistance indirectly through its impact on
decreasing antimicrobial use. Another study in
California found a reduction in the number of
antimicrobial prescriptions among children who
received the conjugate vaccine [57]. There is
concern, however, that non-vaccine serotypes
may begin to emerge as causes of serious infection
as the vaccine serotypes are diminished; as this
occurs it is possible that drug resistance may
emerge among these other serotypes as a result of
the selective pressure of antimicrobial usage.
Nevertheless, the initial impact of this vaccine
has been very positive in reducing the burden of
pneumoccocal disease speciﬁcally, but also in
reducing the amount of resistance.
CONCLUSION
Clinicians need to be cognisant of the aetiological
agents of community RTIs, local antimicrobial
sensitivity patterns, and pharmacological options
for appropriate empirical therapy. S. pneumoniae
is the most signiﬁcant bacterial cause and empi-
rical therapy should target this pathogen, taking
into consideration the possibility of drug-resistant
isolates.
The judicious prescribing of antimicrobial ther-
apy is warranted, not only because it is good
clinical practice, but also because it is necessary to
curtail current patterns of increasing bacterial
resistance to commonly used antimicrobials.
Patient risk factors can be helpful in stratifying
patients for appropriate antibiotic treatment. As
new specimen-sampling techniques and micro-
biological detection methods become available, a
shift from empirical therapy toward pathogen-
directed therapy may result in improved out-
comes and curb antimicrobial resistance.
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